S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
NASDAQ:ANIX

Anixa Biosciences (ANIX) Stock Price, News & Analysis

$3.23
+0.10 (+3.19%)
(As of 03/27/2024 ET)
Today's Range
$3.13
$3.30
50-Day Range
$3.08
$4.96
52-Week Range
$2.75
$6.45
Volume
52,698 shs
Average Volume
146,443 shs
Market Capitalization
$103.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

Anixa Biosciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
271.5% Upside
$12.00 Price Target
Short Interest
Healthy
1.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.56mentions of Anixa Biosciences in the last 14 days
Based on 13 Articles This Week
Insider Trading
Acquiring Shares
$132,900 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.44) to ($0.45) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.90 out of 5 stars

Medical Sector

421st out of 939 stocks

Pharmaceutical Preparations Industry

196th out of 430 stocks

ANIX stock logo

About Anixa Biosciences Stock (NASDAQ:ANIX)

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

ANIX Stock Price History

ANIX Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
ANIX Apr 2024 2.500 put
ANIX Apr 2024 7.500 call
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Recap: Anixa Biosciences Q1 Earnings
Anixa Biosciences Inc (ANIX)
ANIX Feb 2024 5.000 call
See More Headlines
Receive ANIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/12/2024
Today
3/27/2024
Next Earnings (Estimated)
6/12/2024
Fiscal Year End
10/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ANIX
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.00
High Stock Price Target
$12.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+271.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-9,810,000.00
Pretax Margin
-5,174.29%

Debt

Sales & Book Value

Annual Sales
$210,000.00
Book Value
$0.74 per share

Miscellaneous

Free Float
24,691,000
Market Cap
$103.04 million
Optionable
Optionable
Beta
0.85
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Amit Kumar Ph.D. (Age 60)
    CEO, Chairman & Co-Chair of CBAB
    Comp: $1.07M
  • Mr. Michael J. Catelani CPA (Age 57)
    MBA, President, COO, CFO & Corporate Secretary
    Comp: $550.96k
  • Mr. John Roop (Age 74)
    Senior Vice President of Engineering
    Comp: $275k
  • Dr. Pamela D. Garzone Ph.D. (Age 69)
    Chief Development Officer & Chair Breast Cancer Clinical Advisory Board

ANIX Stock Analysis - Frequently Asked Questions

Should I buy or sell Anixa Biosciences stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anixa Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ANIX shares.
View ANIX analyst ratings
or view top-rated stocks.

What is Anixa Biosciences' stock price target for 2024?

1 Wall Street research analysts have issued 12-month price targets for Anixa Biosciences' stock. Their ANIX share price targets range from $12.00 to $12.00. On average, they predict the company's share price to reach $12.00 in the next year. This suggests a possible upside of 271.5% from the stock's current price.
View analysts price targets for ANIX
or view top-rated stocks among Wall Street analysts.

How have ANIX shares performed in 2024?

Anixa Biosciences' stock was trading at $3.88 at the beginning of the year. Since then, ANIX shares have decreased by 16.8% and is now trading at $3.23.
View the best growth stocks for 2024 here
.

When is Anixa Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024.
View our ANIX earnings forecast
.

How were Anixa Biosciences' earnings last quarter?

Anixa Biosciences, Inc. (NASDAQ:ANIX) issued its earnings results on Tuesday, March, 12th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.01.

What other stocks do shareholders of Anixa Biosciences own?
Who are Anixa Biosciences' major shareholders?

Anixa Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.39%), Vanguard Group Inc. (4.39%), UBS Group AG (1.83%), International Assets Investment Management LLC (0.17%), Corient Private Wealth LLC (0.12%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Amit Kumar, Arnold M Baskies, Emily Gottschalk, Lewis H Titterton Jr and Michael Catelani.
View institutional ownership trends
.

How do I buy shares of Anixa Biosciences?

Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ANIX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners